Who are Protara Therapeutics, Inc.'s main suppliers?

Protara Therapeutics, Inc. (TARA) key suppliers include: THE-FEINSTEIN-INSTITUTE-FOR-MEDICAL-RESEARCH, enGene Therapeutics Inc., ENGNW, Palvella Therapeutics, Inc.. View the full supplier network at chainsifter.com/chain/TARA.

Who are Protara Therapeutics, Inc.'s major customers?

Protara Therapeutics, Inc. (TARA) key customers include: Biodexa Pharmaceuticals Plc, enGene Therapeutics Inc., ENGNW, Palvella Therapeutics, Inc., ARTARA-SUBSIDIARY-INC and 3 more. View the full customer network at chainsifter.com/chain/TARA.

What sector is Protara Therapeutics, Inc. in?

Protara Therapeutics, Inc. (TARA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Protara Therapeutics, Inc. Suppliers, Customers & Supply Chain (TARA)

4Suppliers

8Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Protara Therapeutics, Inc. (TARA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships

2Distinct source URLs

5High confidence

0.751Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Protara Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
THE-FEINSTEIN-INSTITUTE-FOR-MEDICAL-RESEARCH	THE-FEINSTEIN-INSTITUTE-FOR-MEDICAL-RESEARCH	90%	As consideration for the license grant, we agreed to pay the Institute tiered royalties of between 1.0% and 1.5% of all net sales.
ENGN	enGene Therapeutics Inc.	72%	Reciprocal relationship from ENGN graph: Reciprocal relationship from TARA graph: Reciprocal relationship from ENGN graph: Reciprocal relationship from TARA graph: Reciprocal relationship from ENGN g…
ENGNW	ENGNW	72%	Reciprocal relationship from ENGNW graph: nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can meet our needs for a commercial launch …
PVLA	Palvella Therapeutics, Inc.	72%	Reciprocal relationship from PVLA graph: Reciprocal relationship from TARA graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from TARA graph: Reciprocal relationship from PVLA g…

Protara Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
BDRX	Biodexa Pharmaceuticals Plc	72%	Reciprocal relationship from BDRX graph: l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, the U.S. Supreme Court held unanimously th…
ENGN	enGene Therapeutics Inc.	72%	Reciprocal relationship from ENGN graph: Reciprocal relationship from TARA graph: Reciprocal relationship from ENGN graph: Reciprocal relationship from TARA graph: Reciprocal relationship from ENGN g…
ENGNW	ENGNW	72%	Reciprocal relationship from ENGNW graph: Reciprocal relationship from TARA graph: Reciprocal relationship from ENGNW graph: nts, drug substance and drug product are currently manufactured at cGMP-co…
PVLA	Palvella Therapeutics, Inc.	72%	Reciprocal relationship from PVLA graph: Reciprocal relationship from TARA graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from TARA graph: Reciprocal relationship from PVLA g…
ARTARA-SUBSIDIARY-INC	ARTARA-SUBSIDIARY-INC	62%	e or fraudulent claim for purposes of the federal False Claims Act, or the FCA. 32 The federal false claims, including the FCA, and civil monetary penalty laws, which imposes significant penalties an…
ARTARA-THERAPEUTICS-INC	ARTARA-THERAPEUTICS-INC	62%	e or fraudulent claim for purposes of the federal False Claims Act, or the FCA. 32 The federal false claims, including the FCA, and civil monetary penalty laws, which imposes significant penalties an…
PROTEON-THERAPEUTICS-INC	PROTEON-THERAPEUTICS-INC	62%	e or fraudulent claim for purposes of the federal False Claims Act, or the FCA. 32 The federal false claims, including the FCA, and civil monetary penalty laws, which imposes significant penalties an…
PROTEON-THERAPEUTICS-LLC	PROTEON-THERAPEUTICS-LLC	62%	e or fraudulent claim for purposes of the federal False Claims Act, or the FCA. 32 The federal false claims, including the FCA, and civil monetary penalty laws, which imposes significant penalties an…

Protara Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
TARA-DEBT	Debt stack $3.1M	90%	Market cache reports total debt of $3.1M.
TARA-DEBT-12879	Warrants outstanding: 1700000	90%	xbrl warrant detail from xbrl 2024-12-31.
TARA-DEBT-12880	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-09-23.

Protara Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Protara Therapeutics, Inc..

Protara Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
TARA-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 114 tracked holders.

Protara Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BDRX	Biodexa Pharmaceuticals Plc	100.00	1	['customer']
ENGNW	enGene Therapeutics Inc.	100.00	1	['customer', 'supplier']
CRSP	CRISPR Therapeutics AG	100.00	2
RLAY	Relay Therapeutics, Inc.	100.00	2
COGT	Cogent Biosciences, Inc.	100.00	2
GSK	GSK plc	100.00	2
ENGN	enGene Therapeutics Inc.	100.00	1	['customer', 'supplier']
RXRX	Recursion Pharmaceuticals, Inc.	100.00	2
TPST	Tempest Therapeutics, Inc.	100.00	2
PVLA	Palvella Therapeutics, Inc.	100.00	1	['customer', 'supplier']
SABS	SAB Biotherapeutics, Inc.	100.00	2
AURA	Aura Biosciences, Inc.	50.00	2
CDMOS	CDMOS	50.00	2
CROS	CROS	50.00	2
JNJ	Johnson & Johnson	50.00	2
SABSW	SAB Biotherapeutics, Inc.	50.00	2
PSTV	Plus Therapeutics, Inc.	50.00	2
NVSEF	Novartis AG	50.00	2
PRGO	Perrigo Company plc	50.00	2
MNKD	MannKind Corporation	50.00	2

Protara Therapeutics, Inc. Supply Chain